

Oyvind S Bruland

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7961929/oyvind-s-bruland-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

123
papers

4,646
citations

30
h-index

66
g-index

127
ext. papers

5,200
ext. citations

3.9
avg, IF

5.13
L-index

#	Paper	IF	Citations
123	Hope as a Lifeline: Imatinib Discontinuation in Patients With Oligometastatic Gastrointestinal Stromal Tumours.. <i>Anticancer Research</i> , 2022 , 42, 955-963	2.3	0
122	Factors Influencing the Therapeutic Efficacy of the PSMA Targeting Radioligand 212Pb-NG001. <i>Cancers</i> , 2022 , 14, 2784	6.6	0
121	Early immunohistochemical detection of pulmonary micrometastases in dogs with osteosarcoma. <i>Acta Veterinaria Scandinavica</i> , 2021 , 63, 41	2	
120	Radon-220 diffusion from 224Ra-labeled calcium carbonate microparticles: Some implications for radiotherapeutic use. <i>PLoS ONE</i> , 2021 , 16, e0248133	3.7	0
119	Evaluation of the PSMA-Binding Ligand Pb-NG001 in Multicellular Tumour Spheroid and Mouse Models of Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	6
118	Multimodal functional imaging for early response assessment in patients with gastrointestinal stromal tumor treated with tyrosine kinase inhibitors. <i>Acta Radiologica</i> , 2021 , 2841851211027389	2	0
117	Calcium Carbonate Microparticles as Carriers of Ra: Impact of Specific Activity in Mice with Intraperitoneal Ovarian Cancer. <i>Current Radiopharmaceuticals</i> , 2021 , 14, 145-153	1.8	2
116	Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial. <i>JAMA Oncology</i> , 2021 , 7, e205865	13.4	17
115	Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021 , 13,	6.6	18
114	In situ Generated 212Pb-PSMA Ligand in a 224Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive Cells. <i>Current Radiopharmaceuticals</i> , 2020 , 13, 130-141	1.8	6
113	Use of a simple form to facilitate communication on long-term consequences of treatment in sarcoma survivors. <i>Clinical Sarcoma Research</i> , 2020 , 10, 2	2.5	1
112	Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [Pb]Pb-NG001 for prostate cancer. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2020 , 63, 129-143	1.9	18
111	Calibration of sodium iodide detectors and reentrant ionization chambers for Pb activity in different geometries by HPGe activity determined samples. <i>Applied Radiation and Isotopes</i> , 2020 , 166, 109362	1.7	4
110	Preoperative accelerated radiotherapy combined with chemotherapy in a defined cohort of patients with high risk soft tissue sarcoma: a Scandinavian Sarcoma Group study. <i>Clinical Sarcoma Research</i> , 2020 , 10, 22	2.5	1
109	Clinical epidemiology and treatment outcomes of spindle cell non-osteogenic bone sarcomas - A nationwide population-based study. <i>Journal of Bone Oncology</i> , 2019 , 14, 002-2	4.5	5
108	Ewing sarcoma of the mobile spine; predictive factors for survival, neurological function and local control. A Scandinavian sarcoma group study with a mean follow-up of 12 years. <i>Journal of Bone Oncology</i> , 2019 , 14, 100216	4.5	4
107	Perspectives on treatment side effects in patients with metastatic gastrointestinal stromal tumour: a qualitative study. <i>Clinical Sarcoma Research</i> , 2019 , 9, 6	2.5	3

106	Prognostic Impact of Proximal Distal Localization in Extremity Long Bone Osteosarcomas. <i>Anticancer Research</i> , 2019 , 39, 2459-2466	2.3	3
105	Ewing Sarcoma in Nepal Treated With Combined Chemotherapy and Definitive Radiotherapy. <i>Journal of Global Oncology</i> , 2019 , 5, 1-10	2.6	2
104	Therapeutic Effect of ^{223}Ra -Labeled Calcium Carbonate Microparticles in Mice with Intraperitoneal Ovarian Cancer. <i>Translational Oncology</i> , 2018 , 11, 259-267	4.9	16
103	Recurrence-Free Survival After Resection of Gastric Gastrointestinal Stromal Tumors Classified According to a Strict Definition of Tumor Rupture: A Population-Based Study. <i>Annals of Surgical Oncology</i> , 2018 , 25, 1133-1139	3.1	19
102	^{223}Ra -labeling of calcium carbonate microparticles for internal ^{223}Ra therapy: Preparation, stability, and biodistribution in mice. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2018 , 61, 472-486	1.9	28
101	Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. <i>European Urology</i> , 2018 , 73, 427-435	10.2	57
100	Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors-A Scandinavian Sarcoma Group Study (SSG XX). <i>European Journal of Cancer</i> , 2018 , 99, 78-85	7.5	20
99	Osteonecrosis of the Jaw in a Patient With Bone Metastatic Prostate Cancer After Long-term Bisphosphonate Treatment With Severe Deterioration Following Radium-223. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 328-331	3.3	2
98	Radiotherapy of Skeletal Metastases 2018 , 809-815		
97	Validity and completeness of the Scandinavian Sarcoma Group Central Register by comparison with a nationwide cohort of patients with osteosarcoma in Norway. <i>Journal of Surgical Oncology</i> , 2018 , 118, 246-247	2.8	2
96	Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort. <i>Acta Oncologica</i> , 2017 , 56, 1317-1323	3.2	10
95	Multimodal treatment of craniofacial osteosarcoma with high-grade histology. A single-center experience over 35 years. <i>Neurosurgical Review</i> , 2017 , 40, 449-460	3.9	10
94	Genome Analysis of Osteosarcoma Progression Samples Identifies FGFR1 Overexpression as a Potential Treatment Target and CHM as a Candidate Tumor Suppressor Gene. <i>PLoS ONE</i> , 2016 , 11, e0163859	3.7	10
93	Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma. <i>PLoS ONE</i> , 2016 , 11, e0165382	3.7	13
92	Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour. <i>Clinical Sarcoma Research</i> , 2016 , 6, 21	2.5	5
91	Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma. <i>Acta Oncologica</i> , 2015 , 54, 25-33	3.2	79
90	Influence of multiple UV exposures on serum cobalamin and vitamin D levels in healthy females. <i>Scandinavian Journal of Public Health</i> , 2015 , 43, 324-30	3	7
89	Prognostic factors and treatment results of high-grade osteosarcoma in norway: a scope beyond the "classical" patient. <i>Sarcoma</i> , 2015 , 2015, 516843	3.1	30

88	Clinical Epidemiology of Low-Grade and Dedifferentiated Osteosarcoma in Norway during 1975 and 2009. <i>Sarcoma</i> , 2015 , 2015, 917679	3.1	36
87	Vitamin D levels and dietary intake among patients with benign soft tissue tumors and sarcomas. <i>Anticancer Research</i> , 2015 , 35, 1171-80	2.3	1
86	Extraskeletal osteosarcoma in Norway, between 1975 and 2009, and a brief review of the literature. <i>Anticancer Research</i> , 2015 , 35, 2129-40	2.3	15
85	Can Imatinib Be Safely Withdrawn in Patients with Surgically Resected Metastatic GIST?. <i>Anticancer Research</i> , 2015 , 35, 5759-65	2.3	2
84	Negative and Positive Consequences of Cancer Treatment Experienced by Long-term Osteosarcoma Survivors: A Qualitative Study. <i>Anticancer Research</i> , 2015 , 35, 6081-90	2.3	12
83	Radiotherapy for spinal metastases from breast cancer with emphasis on local disease control and pain response using repeated MRI. <i>Journal of Bone Oncology</i> , 2014 , 3, 5-9	4.5	5
82	Response to preoperative chemotherapy in patients undergoing resection of pulmonary metastasis from soft tissue sarcoma - a predictor of outcome?. <i>Acta Oncologica</i> , 2014 , 53, 1180-7	3.2	8
81	Multimodal functional imaging for early response assessment in GIST patients treated with imatinib. <i>Acta Oncologica</i> , 2014 , 53, 143-8	3.2	9
80	Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. <i>Lancet Oncology, The</i> , 2014 , 15, 738-46	21.7	357
79	¹⁷⁷ Lu-DOTA-HH1, a novel anti-CD37 radio-immunoconjugate: a study of toxicity in nude mice. <i>PLoS ONE</i> , 2014 , 9, e103070	3.7	17
78	Advantage of lutetium-177 versus radioiodine immunoconjugate in targeted radionuclide therapy of b-cell tumors. <i>Anticancer Research</i> , 2014 , 34, 3263-9	2.3	6
77	Incidence and mortality of second sarcomas - a population-based study. <i>European Journal of Cancer</i> , 2013 , 49, 3292-302	7.5	6
76	Patterns of local recurrence and dose fractionation of adjuvant radiation therapy in 462 patients with soft tissue sarcoma of extremity and trunk wall. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 86, 949-55	4	6
75	Treatment of Osteoblastic Skeletal Metastases by the Alpha-Emitting Bone-Seeker Radium-223. <i>Medical Radiology</i> , 2013 , 447-457	0.2	1
74	Targeted radio-nuclide therapy of skeletal metastases. <i>Cancer Treatment Reviews</i> , 2013 , 39, 18-26	14.4	39
73	Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 20-6	3.3	91
72	Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H. <i>Acta Oncologica</i> , 2013 , 52, 776-82	3.2	13
71	Biologic targets identified from dynamic ¹⁸ F-FDG-PET and implications for image-guided therapy. <i>Acta Oncologica</i> , 2013 , 52, 1378-83	3.2	7

70	Quantitative dynamic 18 F-DG-PET and tracer kinetic analysis of soft tissue sarcomas. <i>Acta Oncologica</i> , 2013 , 52, 1160-7	3.2	11
69	The clinical impact of mean vessel size and solidity in breast carcinoma patients. <i>PLoS ONE</i> , 2013 , 8, e75954	3.4	8
68	Superficial-spreading and nodular melanomas in Norway: a comparison by body site distribution and latitude gradients. <i>Melanoma Research</i> , 2012 , 22, 460-5	3.3	16
67	Global gene expression profiling of human osteosarcomas reveals metastasis-associated chemokine pattern. <i>Sarcoma</i> , 2012 , 2012, 639038	3.1	29
66	Preclinical evaluation of 227 Th-labeled and 177 Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts. <i>Nuclear Medicine Communications</i> , 2012 , 33, 838-47	1.6	21
65	Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2011 , 82, 211-6	4.3	43
64	Five-year results from a Scandinavian sarcoma group study (SSG XIII) of adjuvant chemotherapy combined with accelerated radiotherapy in high-risk soft tissue sarcoma of extremities and trunk wall. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 81, 1359-66	4	15
63	Experimental β particle radioimmunotherapy of breast cancer using 227 Th-labeled p-benzyl-DOTA-trastuzumab. <i>EJNMMI Research</i> , 2011 , 1, 18	3.6	38
62	Monitoring the effect of targeted therapies in a gastrointestinal stromal tumor xenograft using a clinical PET/CT. <i>Molecular Imaging and Biology</i> , 2011 , 13, 1234-40	3.8	11
61	Radiotherapy or surgery for spine metastases?. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2011 , 82, 365-71	4.3	11
60	DW MRI for evaluation of treatment response to imatinib in a rectal gastrointestinal stromal tumour. <i>Acta Oncologica</i> , 2011 , 50, 148-50	3.2	12
59	Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugates. <i>Current Radiopharmaceuticals</i> , 2011 , 4, 321-8	1.8	17
58	Re-Evaluation of CD37 As Target for Radioimmunotherapy of Non-Hodgkin Lymphoma,. <i>Blood</i> , 2011 , 118, 3732-3732	2.2	
57	Latitude gradient for melanoma incidence by anatomic site and gender in Norway 1966-2007. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2010 , 101, 174-8	6.7	25
56	Vitamin D Status, Solar Radiation and Cancer Prognosis 2010 , 765-775		
55	Synchronous and metachronous skeletal osteosarcomas: the Norwegian Radium Hospital experience. <i>Acta Oncologica</i> , 2009 , 48, 1165-72	3.2	15
54	Photochemical internalization of bleomycin before external-beam radiotherapy improves locoregional control in a human sarcoma model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 75, 878-85	4	13
53	DCEMRI of spontaneous canine tumors during fractionated radiotherapy: a pharmacokinetic analysis. <i>Radiotherapy and Oncology</i> , 2009 , 93, 618-24	5.3	10

52	Treatment of osteosarcoma. The Scandinavian Sarcoma Group experience. <i>Cancer Treatment and Research</i> , 2009 , 152, 309-18	3.5	17
51	Bone marrow micrometastases studied by an immunomagnetic isolation procedure in extremity localized non-metastatic osteosarcoma patients. <i>Cancer Treatment and Research</i> , 2009 , 152, 509-15	3.5	9
50	Radiological and functional assessment of radiation-induced pulmonary damage following breast irradiation. <i>Acta Oncologica</i> , 2008 , 47, 248-54	3.2	13
49	DCEMRI monitoring of canine tumors during fractionated radiotherapy. <i>Acta Oncologica</i> , 2008 , 47, 1249-56	3.2	9
48	Disseminated tumor cells in bone marrow following definitive radiotherapy for intermediate or high-risk prostate cancer. <i>Prostate</i> , 2008 , 68, 1607-14	4.2	4
47	Sun beds and cod liver oil as vitamin D sources. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2008 , 91, 125-31	6.7	38
46	Radiotherapy to improve local control regardless of surgical margin and malignancy grade in extremity and trunk wall soft tissue sarcoma: a Scandinavian sarcoma group study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 71, 1196-203	4	98
45	Relative biologic effects of low-dose-rate alpha-emitting ²²⁷ Th-rituximab and beta-emitting ⁹⁰ Y-tiuexetan-ibrutumomab versus external beam X-radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 72, 186-92	4	29
44	Targeted High-LET Therapy of Bone Metastases 2008 , 181-194		1
43	Seasonal and geographical variations in lung cancer prognosis in Norway. Does Vitamin D from the sun play a role?. <i>Lung Cancer</i> , 2007 , 55, 263-70	5.9	83
42	Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. <i>International Journal of Cancer</i> , 2007 , 120, 1603-9	7.5	45
41	Radiotherapy adapted to spatial and temporal variability in tumor hypoxia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 68, 1496-504	4	65
40	10-year survival and quality of life in patients with high-risk pN0 prostate cancer following definitive radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 69, 1074-83	4	11
39	Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: a modelling study. <i>Physics in Medicine and Biology</i> , 2007 , 52, 499-513	3.8	66
38	Some musculo-skeletal sequelae in cancer survivors. <i>Acta Oncologica</i> , 2007 , 46, 490-6	3.2	20
37	Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate. <i>Blood</i> , 2007 , 110, 2049-56	2.2	69
36	Proton therapy - a systematic review of clinical effectiveness. <i>Radiotherapy and Oncology</i> , 2007 , 83, 123-32	3.2	140
35	Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. <i>Lancet Oncology</i> , 2007 , 8, 587-94	21.7	397

34	Preparation of TH227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007 , 22, 431-7	3.9	37
33	Management of high-grade bone sarcomas over two decades: the Norwegian Radium Hospital experience. <i>Acta Oncologica</i> , 2006 , 45, 38-46	3.2	29
32	High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?. <i>Clinical Cancer Research</i> , 2006 , 12, 6250s-6257s	12.9	243
31	Adapting radiotherapy to hypoxic tumours. <i>Physics in Medicine and Biology</i> , 2006 , 51, 4903-21	3.8	61
30	Initial evaluation of (227)Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy. <i>Nuclear Medicine and Biology</i> , 2006 , 33, 271-9	2.1	49
29	TP-3 immunotoxins improve antitumor activity in mice with osteosarcoma. <i>Clinical Orthopaedics and Related Research</i> , 2005 , 142-8	2.2	9
28	Primary osteosarcoma of the breast. <i>Acta Oncologica</i> , 2005 , 44, 767-70	3.2	14
27	First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. <i>Clinical Cancer Research</i> , 2005 , 11, 4451-9	12.9	360
26	Telemedicine in radiotherapy: a study exploring remote treatment planning, supervision and economics. <i>Journal of Telemedicine and Telecare</i> , 2005 , 11, 245-50	6.8	25
25	Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. <i>Cancer Research</i> , 2004 , 64, 4768-73	10.1	182
24	Radiation improves the distribution and uptake of liposomal doxorubicin (caelyx) in human osteosarcoma xenografts. <i>Cancer Research</i> , 2004 , 64, 547-53	10.1	126
23	Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. <i>Journal of Nuclear Medicine</i> , 2003 , 44, 252-9	8.9	163
22	Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. <i>Cancer Research</i> , 2002 , 62, 3120-5	10.1	192
21	Synthesis, purification and biodistribution of (205)Bi-DOTMP, visualizing bone deposition patterns with autoradiography. <i>Nuclear Medicine and Biology</i> , 2001 , 28, 425-33	2.1	10
20	Cytotoxicity of Antiosteosarcoma Recombinant Immunotoxins Composed of TP-3 Fv Fragments and a Truncated Pseudomonas Exotoxin A. <i>Journal of Immunotherapy</i> , 2001 , 24, 144-150	5	14
19	Telemedicine in radiotherapy treatment planning: requirements and applications. <i>Radiotherapy and Oncology</i> , 2000 , 54, 255-9	5.3	42
18	Two human osteoblast-like osteosarcoma cell lines show distinct expression and differential regulation of parathyroid hormone-related protein. <i>Journal of Bone and Mineral Research</i> , 1999 , 14, 904-14	6.2	3
17	Complement-mediated lysis of cultured osteosarcoma cell lines using chimeric mouse/human TP-1 IgG1 and IgG3 antibodies. <i>Cancer Immunology, Immunotherapy</i> , 1999 , 48, 411-8	7.4	5

16	Influence of pretreatment with 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APB) on organ uptake of ²¹¹ At and ¹²⁵ I-labeled amidobisphosphonates in mice. <i>Nuclear Medicine and Biology</i> , 1999 , 26, 791-4	2.1	13
15	Preliminary evaluation of a new radiolabelled biphosphonate. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1998 , 41, 823-830	1.9	3
14	IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic cells. <i>Immunotechnology: an International Journal of Immunological Engineering</i> , 1998 , 4, 141-53		15
13	Targeted radiotherapy of osteosarcoma using ¹⁵³ Sm-EDTMP. A new promising approach. <i>Acta Oncologica</i> , 1996 , 35, 381-4	3.2	67
12	Abundant tyrosine residues in the antigen binding site in anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Application to radiolabeling. <i>Acta Oncologica</i> , 1996 , 35, 297-301	3.2	13
11	Extremity and non-extremity high-grade osteosarcoma -- the Norwegian Radium Hospital experience during the modern chemotherapy era. <i>Acta Oncologica</i> , 1996 , 35 Suppl 8, 129-34	3.2	25
10	Diverse expression of G-proteins in human sarcoma cell lines with different osteogenic potential: Evidence for the involvement of Gi2 in cell proliferation. <i>Journal of Cellular Biochemistry</i> , 1996 , 60, 95-106	4.7	4
9	Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: location of lysine residues and implications for radiolabeling. <i>Nuclear Medicine and Biology</i> , 1995 , 22, 765-71	2.1	16
8	Alpha-particle radiotherapy with ²¹¹ At-labeled monodisperse polymer particles, ²¹¹ At-labeled IgG proteins, and free ²¹¹ At in a murine intraperitoneal tumor model. <i>Gynecologic Oncology</i> , 1995 , 57, 9-15	4.9	415
7	Cancer therapy with radiolabeled antibodies. An overview. <i>Acta Oncologica</i> , 1995 , 34, 1085-94	3.2	7
6	Radiolysis of radioimmunoconjugates. Reduction in antigen-binding ability by β particle radiation. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1995 , 36, 1009-1018	1.9	8
5	²¹² Pb/ ²¹² Bi-EDTMP synthesis and biodistribution of a novel bone seeking alpha-emitting radiopharmaceutical. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1994 , 34, 717-734	1.9	15
4	Preparation and quality control of ²¹¹ At-labelled and ¹²⁵ I-labelled monoclonal antibodies. Biodistribution in mice carrying human osteosarcoma xenografts. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1994 , 34, 773-785	1.9	11
3	Inactivation of Human Osteosarcoma Cells In Vitro by ²¹¹ At-TP-3 Monoclonal Antibody: Comparison with Astatine-211-Labeled Bovine Serum Albumin, Free Astatine-211 and External-Beam X Rays. <i>Radiation Research</i> , 1994 , 139, 178	3.1	26
2	Radiotherapy of Skeletal Metastases754-759		
1	Chapter 86. Radiotherapy of Skeletal Metastases404-407		1